Suppr超能文献

感染人类免疫缺陷病毒者的肝脏相关死亡:D:A:D研究

Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study.

作者信息

Weber Rainer, Sabin Caroline A, Friis-Møller Nina, Reiss Peter, El-Sadr Wafaa M, Kirk Ole, Dabis Francois, Law Matthew G, Pradier Christian, De Wit Stephane, Akerlund Börje, Calvo Gonzalo, Monforte Antonella d'Arminio, Rickenbach Martin, Ledergerber Bruno, Phillips Andrew N, Lundgren Jens D

机构信息

Division of Infectious Diseases and Hospital Epidemiology, University Hospital, CH-809a Zurich, Switzerland.

出版信息

Arch Intern Med. 2006;166(15):1632-41. doi: 10.1001/archinte.166.15.1632.

Abstract

BACKGROUND

An increasing proportion of deaths among human immunodeficiency virus (HIV)-infected persons with access to combination antiretroviral therapy (cART) are due to complications of liver diseases.

METHODS

We investigated the frequency of and risk factors associated with liver-related deaths in the Data Collection on Adverse Events of Anti-HIV Drugs study, which prospectively evaluated 76 893 person-years of follow-up in 23 441 HIV-infected persons. Multivariable Poisson regression analyses identified factors associated with liver-related, AIDS-related, and other causes of death.

RESULTS

There were 1246 deaths (5.3%; 1.6 per 100 person-years); 14.5% were from liver-related causes. Of these, 16.9% had active hepatitis B virus (HBV), 66.1% had hepatitis C virus (HCV), and 7.1% had dual viral hepatitis co-infections. Predictors of liver-related deaths were latest CD4 cell count (adjusted relative rate [RR], 16.1; 95% confidence interval [CI], 8.1-31.7 for <50 vs > or =500/microL), age (RR, 1.3; 95% CI, 1.2-1.4 per 5 years older), intravenous drug use (RR, 2.0; 95% CI, 1.2-3.4), HCV infection (RR, 6.7; 95% CI, 4.0-11.2), and active HBV infection (RR, 3.7; 95% CI, 2.4-5.9). Univariable analyses showed no relationship between cumulative years patients were receiving cART and liver-related death (RR, 1.00; 95% CI, 0.93-1.07). Adjustment for the most recent CD4 cell count and patient characteristics resulted in an increased risk of liver-related mortality per year of mono or dual antiretroviral therapy before cART (RR, 1.09; 95% CI, 1.02-1.16; P = .008) and per year of cART (RR, 1.11; 95% CI, 1.02-1.21; P = .02).

CONCLUSIONS

Liver-related death was the most frequent cause of non-AIDS-related death. We found a strong association between immunodeficiency and risk of liver-related death. Longer follow-up is required to investigate whether clinically significant treatment-associated liver-related mortality will develop.

摘要

背景

在接受联合抗逆转录病毒疗法(cART)的人类免疫缺陷病毒(HIV)感染者中,因肝脏疾病并发症导致的死亡比例日益增加。

方法

我们在抗HIV药物不良事件数据收集研究中调查了与肝脏相关死亡的频率及相关危险因素,该研究对23441名HIV感染者进行了前瞻性评估,随访时间达76893人年。多变量泊松回归分析确定了与肝脏相关、艾滋病相关及其他死亡原因相关的因素。

结果

共有1246例死亡(5.3%;每100人年1.6例);14.5%的死亡由肝脏相关原因导致。其中,16.9%患有活动性乙型肝炎病毒(HBV)感染,66.1%患有丙型肝炎病毒(HCV)感染,7.1%患有两种病毒的合并感染。肝脏相关死亡的预测因素包括最近的CD4细胞计数(调整后的相对率[RR]为16.1;95%置信区间[CI],CD4细胞计数<50/μL与≥500/μL相比为8.1 - 31.7)、年龄(RR为1.3;95%CI,每增加5岁为1.2 - 1.4)、静脉吸毒(RR为2.0;95%CI,1.2 - 3.4)、HCV感染(RR为6.7;95%CI,4.0 - 11.2)以及活动性HBV感染(RR为3.7;95%CI,2.4 - 5.9)。单变量分析显示患者接受cART的累积年数与肝脏相关死亡之间无关联(RR为1.00;95%CI,0.93 - 1.07)。对最近的CD4细胞计数和患者特征进行调整后发现,在开始cART之前,单药或双药抗逆转录病毒治疗每年会增加肝脏相关死亡风险(RR为1.09;95%CI,1.02 - 1.16;P = 0.008),cART治疗每年也会增加该风险(RR为1.11;95%CI,1.02 - 1.21;P = 0.02)。

结论

肝脏相关死亡是艾滋病无关死亡最常见的原因。我们发现免疫缺陷与肝脏相关死亡风险之间存在密切关联。需要更长时间的随访来研究是否会出现具有临床意义且与治疗相关的肝脏相关死亡率。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验